Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DNF95E
|
|||
| Drug Name |
Nirsevimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Lower respiratory tract infection [ICD-11: CA45; ICD-10: J09-J99; ICD-9: 480-519] | Approved | [1] | |
| Respiratory syncytial virus infection [ICD-11: 1C80; ICD-9: 79.6] | Phase 2 | [2] | ||
| Company |
AstraZeneca
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761328 | |||
| REF 2 | ClinicalTrials.gov (NCT04484935) Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.